Larimar Therapeutics' stock has surged 170% in the last year, despite being an unprofitable business. With a strong cash position and low cash burn relative to market cap, the company seems well-equipped to fund its growth.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing